| Cat. Number | W9600 |
||||||||||||||||||||
| Chemical Name | WZ-4002 |
||||||||||||||||||||
| CAS Number | 1213269-23-8 |
||||||||||||||||||||
| Mol. Formula | C25H27ClN6O3 |
||||||||||||||||||||
| Mol. Weight | 494.97 |
||||||||||||||||||||
| Qty 1 |
1mg |
||||||||||||||||||||
| Appearance | White Powder |
||||||||||||||||||||
| Application Notes | ≥98% |
||||||||||||||||||||
| Solubility | DMSO 13 mg/mL (26.3 mM) Water Insoluble Ethanol Insoluble |
||||||||||||||||||||
| Storage condition | -20°C |
||||||||||||||||||||
| References | WZ-4002 inhibits EGFR in a variety of cell lines, including those harboring the T790M gatekeeper mutation. WZ-2004 exhibits anticancer chemotherapeutic activity, inhibiting proliferation of lung adenocarcinoma cells and suppressing tumor growth in animal models. Product Info
Shipping and Storage
Downloads
ReferencesNakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012 Oct;11(10):2149-57. PMID: 22844075. Sakuma Y, Yamazaki Y, Nakamura Y, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012 Mar;92(3):371-83. PMID: 22157722. |
||||||||||||||||||||
